• >33 Million patients diagnosed with atrial fibrillation (Afib) globally
  • Afib is the leading cause of stroke (up to 15% of strokes)
  • Afib ablation market is $1.7 Billion (CAGR 12-15%)
  • Estimated 500K Afib ablations/year globally (3% market penetration)
  • “Single-shot” devices outpacing market growth by up to 5%

The most successful and fundamental treatment for atrial fibrillation is ablation  – specifically pulmonary vein ablation or isolation (PVI). PVI is a procedure that is performed in hundreds of thousands of patients around the world every year, but up to 30% of patients have a recurrence and need repeat procedures.

Recurrence is most often due to inconsistent electrode-tissue contact and/or gaps in the lesion set delivered.

ElectroPhysiology Frontiers is developing an innovative, easy to use “single shot” catheter ablation system with a unique design to reduce the rate of recurrence of Atrial Fibrillation (AFib) after pulmonary vein ablation (PVI).